Cipla Ltd. Announces 60:40 Joint Venture with Kemwell Biopharma for Biologics Manufacturing

Cipla Ltd. has entered into a joint venture agreement with Kemwell Biopharma Private Limited to incorporate a joint venture company in India. The joint venture will develop, manufacture, and commercialize biologic products for global markets. Kemwell, a premier Asia-based biologics CDMO, offers end-to-end services for global biopharma clients and has a US FDA-certified cGMP site in Bangalore with 5,000 L bioreactor capacity, sterile fill-finish, and advanced development labs for protein therapeutics. The joint venture partners will initially invest up to INR 10 crores in the JV Company in their respective JV ratio.